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E D I T O R I A L S
Liver enzymes and all‐cause mortality: Open issues
Elevated	serum	levels	of	aspartate	aminotransferase	(AST),	gamma‐
glutamyltransferase	 (GGT)	 and	 alanine	 aminotransferase	 (ALT)	 are	





















were	 significant	 after	 allowance	 for	 a	 large	number	of	 risk	 factors,	
including	tobacco,	alcohol,	body	mass	index	(BMI),	physical	activity,	
energy	intake,	hypertension,	hyperglycaemia	and	dyslipidaemia.
The	 associations	 between	 liver	 enzymes	 and	 non	 liver	 disease	
mortality	were	however	inconsistent	in	subjects	positive	for	hepatitis	
virus	infection,	i.e.	subjects	with	HBV	surface	antigen	and/or	anti‐HCV	
antibody	 serum	 markers.	 In	 those	 subjects,	 liver	 disease	 mortality	




















Thus,	 the	 excess	non	 liver	 disease	mortality	 among	HBV/HCV	


























colorectal,	 post‐menopausal	 breast,	 ovarian,	 gallbladder	 and	 thyroid	
cancers.13	 Type	 2	 diabetes	 is	 a	 risk	 factor	 for	 liver	 cancer	 and	 col‐
orectal,	pancreatic,	endometrial	and	perhaps	post‐menopausal	breast	
cancer.14,15	There	 is	 also	 some	 indication	 for	an	association	between	
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Thus,	 given	 the	presence	of	 common	 risk	 factors	 for	non	viral	
liver	diseases	and	other	leading	causes	of	death,	it	is	plausible	that	





patible	 to	 some	excess	 deaths	 among	 subjects	with	 elevated	 liver	
enzymes.	This	 is	reasonable,	 since	AST,	ALT	and	GGT	are	markers	










a	 role	of	 these	markers	 as	 indicators	of	 non	 liver	disease	mortality	
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